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The FOXO family of transcription factors is central to the regulation of organismal
longevity and cellular survival. Several studies have indicated that FOXO factors lie at the
center of a complex network of upstream pathways, cofactors and downstream targets
(FOXO-interaction networks), which may have developmental and post-developmental
roles in the regulation of chronic-stress response in normal and diseased cells. Noticeably,
FOXO factors are important for the regulation of proteotoxicity and neuron survival in
several models of neurodegenerative disease, suggesting that FOXO-interaction networks
may have therapeutic potential. However, the status of FOXO-interaction networks in
neurodegenerative disease remains largely unknown. Systems modeling is anticipated
to provide a comprehensive assessment of this question. In particular, interrogating
the context-dependent variability of FOXO-interaction networks could predict the clinical
potential of cellular-stress response genes and aging regulators for tackling brain and
peripheral pathology in neurodegenerative disease. Using published transcriptomic data
obtained from murine models of Huntington’s disease (HD) and post-mortem brains, blood
samples and induced-pluripotent-stem cells from HD carriers as a case example, this
review briefly highlights how the biological status and clinical potential of FOXO-interaction
networks for HD may be decoded by developing network and entropy based feature
selection across heterogeneous datasets.
Keywords: Huntington’s disease, cellular-stress response, FOXO network, clinical potential, gene prioritization,
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INTRODUCTION
The FOXO family of transcription factors is well-known for its
effect in regulating longevity as initially uncovered in the nema-
tode C. elegans (Kenyon et al., 1993). This activity of FOXO pro-
teins may hold true in humans since allelic variation in FOXO3A
was associated with the ability to be long-lived in several popula-
tions of centenarians (Willcox et al., 2008; Anselmi et al., 2009;
Flachsbart et al., 2009; Li et al., 2009; Soerensen et al., 2010;
Kleindorp et al., 2011). Besides their role as longevity-promoting
factors, FOXO proteins are known to regulate a variety of biolog-
ical processes which are important for development, metabolism
and tumor suppression (Calnan and Brunet, 2008). Multiple
studies have indicated that FOXO factors may lie at the center
of a complex network of upstream pathways such as the PI3K-
AKT (insulin/IGF-1 signaling cascade), MST-1, JNK, SIR-2, and
AMPK pathways, cofactors such as 14-3-3 proteins and ß-catenin
and a fairly large number of either established or putative tran-
scriptional targets. This notion has been extensively reviewed in
several articles to which to refer for more details (Greer and
Brunet, 2005; Calnan and Brunet, 2008; Landis and Murphy,
2010; Yen et al., 2011; Neri, 2012; Eijkelenboom and Burgering,
2013). These studies have emphasized a model in which, through
a series of context-dependent post-translational modifications
and nucleo-cytoplasmic interactions, FOXO proteins are signal
integrators that may be repressed by insulin/IGF-1 signaling and
that may function developmentally or post-developmentally to
modulate cell cycle arrest, apoptosis, autophagy, angiogenesis,
differentiation, stress resistance, stem cell maintenance, glucoge-
nesis, and food intake.
Consistent with their role in protecting from chronic-stress
in a variety of cellular contexts, FOXO factors and interactors
such as sir-2.1/SIRT1 and ß-catenin also regulate cellular pro-
teotoxicity and neuron survival in models for neurodegenerative
diseases such as Huntington’s disease (HD) (Morley et al., 2002;
Parker et al., 2005, 2012; Burnett et al., 2011) and Alzheimer’s
disease (AD) (Cohen et al., 2006; Kim et al., 2007). The same
notion has been exemplified in more generic models of neu-
rodegeneration (Calixto et al., 2012) and models for muscle cell
dysfunction in oculo-pharyngeal muscular dystrophy (Catoire
et al., 2008; Pasco et al., 2010). Interestingly, the protective effect
of reducing the insulin/IGF-1 signaling cascade—which activates
FOXO, is conserved from C. elegans to mammals (Cohen et al.,
2009; Freude et al., 2009; Killick et al., 2009). FOXO proteins
are not the sole proteins that may regulate cellular proteotoxic-
ity by acting downstream to the insulin/IGF-1 signaling cascade
as other transcription factors such as the heat shock factor HSF-1
may also be involved (Cohen et al., 2010; Teixeira-Castro et al.,
2011; Zhang et al., 2011; Chiang et al., 2012). Collectively, these
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observations suggest that the activity of stress-response networks
such as FOXO-interaction networks could modify the speed at
which the pathogenic process develops in neurodegenerative dis-
ease. The FOXO-interaction networks contain several genes that
are both potential drug targets (Russ and Lampel, 2005) and
evolutionary-conserved, which provides a positive framework for
investigating whether these networks might contain targets and
markers of interest to tackle neurodegenerative diseases such as
HD and AD.
PATHWAYS TO DECODING THE CLINICAL VALUE OF
FOXO-INTERACTION NETWORKS
Given the importance of FOXO-interaction networks for the
regulation of cellular homeostasis, understanding the cellular,
mechanistic and time requirements for these networks to regu-
late diseased neuron resistance and, possibly, modify the onset
and progression of neurodegenerative disease has great thera-
peutic implications. Insight into this question may be provided
by the unbiased analysis of stress-response network activity. One
challenge is to identify the FOXO targets that may be involved
in neuronal resistance in specific neurodegenerative disease con-
ditions. Another challenge is to define the clinical potential of
this information, which may be achieved by means of candi-
date gene prioritization. The knowledge required to prioritize
genes in stress-response networks can be found in molecular pro-
file datasets such as transcriptomic data. As molecular profile
datasets are becoming increasingly available for studying neu-
rodegenerative disease, a timely question is whether there is some
supporting evidence for specific genes in FOXO-interaction net-
works to regulate the pathogenic process in neurodegenerative
disease. A related question is whether some of these genes could
be viewed as “privileged disease targets” whereas other genes
might be viewed as “privileged predictors” of disease onset and
progression. Here, the analysis of HD datasets may provide some
answers.
HUNTINGTON’S DISEASE DATASETS
HD is a dominantly-inherited disease with CAG expansion in
the huntingtin (htt) gene and expanded polyglutamine (polyQ)
tracts in the htt protein causing striatal and cortical degenera-
tion (Walker, 2007). While HD is inherited, this disease shows
a great deal of phenotypic variability and has become a subject
of intense research to understand neurodegenerative disease biol-
ogy due to genetic tractability, large number of models across
species, shared disease mechanisms between HD and other neu-
rodegenerative diseases (Zuccato et al., 2010) and availability of
well-characterized cohorts of HD subjects (Orth et al., 2011).
Among the many genes that could be targeted in HD (Zuccato
et al., 2010), those genes which belong to stress response net-
works are of high interest as they regulate survival mechanisms
that may be central to diseased-neuron resistance. Stress response
networks encompass a large number of pathways that have been
interrogated in genome-wide studies. Most particularly, tran-
scriptomic data have been generated from (1) the striatum of
several murine models of HD such as N-terminal htt transgenic
mice R6/2 (at 6 and 12 weeks) and D9-N171-98Q (a.k.a. DE5;
at 14 months) (Kuhn et al., 2007; Thomas et al., 2011), full
length htt transgenic mice YAC128 (at 12 and 24 months) and
knock-in mice CHL2 (at 22 months) and HdH(Q92/Q92) (at
18 months) and (2) caudate nucleus and BA4/BA9 cortex from
post-mortem HD brains (Hodges et al., 2006), blood samples
from pre-symptomatic and symptomatic HD carriers (Borovecki
et al., 2005) and HD induced pluripotent stem (iPS) cells that
were differentiated into neural stem cell (NSC) lines and that
expressed 60 or 180 CAG repeats (2012). This represents a total
of 14 HD contexts (seven murine and seven human contexts), all
of them assessed on Affymetrix platforms. It is important to note
that these 14 HD-related studies are heterogeneous in terms of
htt gene species, genetic background, cellular/tissular context and
pathological stage (Table S1). Additionally, there might be some
level of cross-studies variability. Nonetheless, these data provide a
case example to illustrate how the status and properties of FOXO-
interaction networks might be explored in HD in the context of
heterogeneous datasets.
FOXO-INTERACTION NETWORKS
Putative targets of mammalian FOXO, namely FOXO3, have been
identified in mouse NSCs (Paik et al., 2009; Renault et al., 2009;
Ro et al., 2012), which represents a total of 374 genes emphasized
by either study. As inferred from the probabilistic functional net-
work STRING (Franceschini et al., 2013), 350 out of 374 mouse
FOXO3 targets have a total of 5859 high-confidence (STRING
score > 0.4) and first-degree interactors. This analysis results in a
FOXO3-interaction network that contains 6209 genes (Figures 1,
S1; Table S2) and that shows a large proportion of evolutionary-
conserved genes. This network has small-world network charac-
teristics (network in which most genes are not neighbors of one
another, but most genes can be reached from every other by a
small number of interactions), which may reflect the existence of
“functional units” in this network. Several FOXO3 target groups
are represented in this network, comprising, for example, genes
involved in mTor signaling, p53 signaling, metabolic pathways,
glycolysis, regulation of actin skeleton, cancer pathways, focal
adhesion and cell cycle (Figure S1).
Intersecting this information with the HD microarray data
abovementioned and selecting the genes which are instructed by
at least 6 contexts within species and 11 contexts across species
retains 4436 genes frommurine datasets, 4881 genes from human
datasets—here the best reciprocal hits as indicated by Ensembl
(http://www.ensembl.org/), and 4634 genes from both murine
and human datasets. What may be the behavior of these genes
across HD contexts? This question can be addressed by using
entropy based feature selection.
ENTROPY BASED FEATURE SELECTION
Entropy is a mathematically defined quantity that helps to
account for the flow of information through a biologically reg-
ulated process, and this quantity can be defined for individual
genes as inferred from the change in status or level of activity
across a number of experimental contexts. High gene-entropy
values indicate context-dependent activity, and, conversely, low
gene-entropy values indicate context-independent activity. In
other words, entropy—as per mRNA-level standard, is a mea-
sure of how dependent is the variation of gene expression level
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FIGURE 1 | Example of FOXO3-interaction network. Putative FOXO3
targets (orange nodes) as indicated by studies in mouse NSCs (Paik
et al., 2009; Renault et al., 2009) with their first-degree neighbors
(violet nodes) as inferred from the probabilistic functional network
STRING. This corresponds to 255 FOXO3 targets that have 2689 first
neighbors in STRING (confidence score greater than 0.7) out of the 374
putative targets initially identified by the Paik et al. and Renault et al.
studies. The confidence score was set at 0.7 to ensure clarity of the graph.
Biological content is illustrated in Figure S1.
on experimental context. In so far, entropy allows detecting the
genes that may be particularly important for adaptability and
homeostasis across cell types and across time. Regarding HD
datasets (Table S1), entropy allows detecting the genes that may
be particularly important for adaptability and response to mutant
htt expression in specific cell types and species, and as pathol-
ogy develops. A simple entropy analysis (Fuhrman et al., 2000)
of HD datasets in which the signal is the change of gene sta-
tus among three possibilities (up-regulated, down-regulated, no
effect) allows genes with low-to-high entropy values to be iden-
tified in FOXO-interaction networks (Figure 2; Tables S3–5),
which is also true when considering gene subsets such as FOXO3
targets (Paik et al., 2009; Renault et al., 2009; Ro et al., 2012)
and potential drug targets (Russ and Lampel, 2005). Permutation
analysis and statistical comparisons of gene entropy distributions
before and after permutations (Mielke and Berry, 2007) suggests
that these observations did not occur by chance (Figure S2). In
these networks, FOXO1 and FOXO3 showed moderate to high
entropy values across datasets (except, however, for FOXO3 across
human datasets). The sirtuin SIRT1 showed high entropy val-
ues and sirtuin SIRT3 showed moderate entropy values across the
murine and murine/human datasets (Tables S3–5). These obser-
vations are consistent with the notion that SIRTs such as SIRT1
and FOXOs such as FOXO3 may be highly sensitive to the context
(cell type, species) in which they operate and they support the
previously-emphasized importance of these genes in regulating
mutant htt cytotoxicity (Parker et al., 2005, 2012; Jeong et al.,
2011; Jiang et al., 2011; Fu et al., 2012).
Overall, it appears that the numbers of very high entropy
(>0.4) genes are much smaller compared to that of low-to-
moderate entropy genes, a trend notably illustrated by gene-
entropy distributions across the 14 mouse and human contexts
(Figure 2). This suggests that a rather limited proportion of
genes in FOXO3-interaction networks might be highly sensitive to
change in cellular context. While this might be unexpected con-
sidering that FOXO pathways are believed to be highly context-
dependent, the genes that have middle to high entropy values
(>0.2) are in larger numbers and may also be involved in context
dependency. Additionally, the signal analyzed herein is based on
the change of gene status, and not the amplitude of this change,
which may limit the sensitivity of the analysis.
How about the biological content of gene-entropy categories?
Enrichment analysis using KEGG annotations (Kanehisa et al.,
2002) suggests that low-to-high entropy gene categories signifi-
cantly differ in biological content, a phenomenon that is true for
FOXO3 targets as well as larger gene sets and that is observed
within and across species (Figures 3, 4). More precisely, gene-
entropy categories may have specific KEGG-pathway profiles,
and a given gene-entropy category may change biological pro-
file across models of HD, providing a comprehensive view on
how cells and tissues might respond to mutant htt expression
within and across species. For example, regarding FOXO3 tar-
gets (Figure 3; Tables S6–8), the pathway “regulation of actin
cytoskeleton” is specific to low-entropy genes in murine striatum
datasets whereas it is specific to high-entropy genes in human
datasets. This suggests that whereas this pathway may poorly
respond to variable contexts such as htt gene species in HD
mice, it may greatly respond to variable contexts such as cellu-
lar context (e.g., caudate nucleus, cortex, blood, and iPS cells) as
contributed by the human datasets. Similar clear-cut evidences
are provided by the KEGG-pathway profiles when considering
FOXO3 targets and their high confidence first-degree neighbors
(Figures 4, S3–5; Tables S9–11). For example, the annotation of
gene-entropy categories corresponding to all datasets (14 con-
ditions) highlights pathways that are more specifically linked to
low, middle or high entropy (Figures 4, S6), providing a global
signature for the biological significance of gene entropy cate-
gories. Interestingly, this signature dramatically changes when
considering either murine or human datasets only (Figures S4,
S5; Tables S10, S11), illustrating how FOXO3-interaction net-
works may be sensitive to the HD context(s) in which they
operate.
How is this translated at the gene level? If considering a
rather homogeneous group of conditions, here murine striatum
datasets, it appears that the corresponding FOXO3-interaction
network mostly contain low entropy genes, suggesting that few
genes only (medium to high entropy genes) such as for exam-
ple FOXO1 (Table S6) may respond to change of context (e.g.,
htt gene species, genetic background, pathological stage) across
murine models (Figure 5A). In contrast, many of the previously
low-entropy genes such as for example the PTEN and DUSP6
phosphatases (Tables S6, S8) become middle-to-high entropy
genes when adding the context variability associated to the human
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FIGURE 2 | Gene entropy values across murine and human datasets.
Datasets (seven conditions in the mouse and seven conditions in humans)
are listed in the main text. Gene entropy values are shown for three
categories of genes (all genes, FOXO3 targets only, druggable genes only)
and for genes which are (1) retained by intersecting transcriptomic and
gene-interaction data and (2) further instructed by at least six conditions in
the mouse, six conditions in humans and 11 conditions in both species. The
maximally achievable entropy value in these analyzes is 0.5. The
corresponding gene lists are shown in Tables S3–5 as organized by species
or across species and as shown for all numbers of instructive conditions.
datasets (Figure 5B). This illustrates how the response of FOXO3-
interaction networks to a change of context across HD-related
conditions may be precisely mapped at the gene level (see also
Figure S6). In summary, the examples provided herein illustrate
how entropy based feature selection may allow stress response
genes to be finely prioritized in HD. Of note, these examples are
biased toward a FOXO3-interaction network that was selected
“by hand” for the purpose of illustration. As such, they do not
constitute final results nor they support final conclusions.
GENE PRIORITIZATION USING ENTROPY BASED FEATURE SELECTION
Many pathways may be closely related to the pathogenesis of
neurodegenerative diseases such as HD. While hypothesis-driven
approaches may allow the pathological or protective role of these
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FIGURE 3 | Heat-maps illustrating the biological content of FOXO3
target genes as a function of gene entropy values. Biological
content is inferred using enrichment in KEGG pathways (P < 0.001) for
three (arbitrarily selected) entropy categories corresponding to low,
middle and high entropy values. The color code indicates − log
P -values.
pathways to be predicted, it remains unclear how these path-
ways may behave across multiple experimental models, whether
they may be prominently associated to specific contexts and
how this may impact on gene prioritization. The approach illus-
trated herein provides a glimpse of this problem. In particular,
this approach roughly highlights two categories of genes includ-
ing genes with a rather limited (low entropy genes or “stable
genes”) or significant (moderate to high entropy genes or “unsta-
ble genes”) change of status across HD conditions. What is the
significance of gene-entropy categories for prioritizing candi-
date disease targets? Whereas one may propose to employ stable
genes as “privileged candidate targets” since the way to manip-
ulate their activity in order to protect from the disease would
make little doubt, other may consider that stable genes are targets
of poor interest because they are unlikely to reflect the changes
that may occur in specific disease contexts (e.g., cellular contexts,
time requirements). These two possibilities are two perspectives
on a single property, namely, the ability to change status across
contexts. The negative perspective highlights insufficient selectiv-
ity in responding to a particular context, which might become
practically useless in discovery efforts aiming at targeting spe-
cific aspects of the disease process. However, low entropy across
heterogeneous datasets might constitute a preferred criterion for
prioritizing candidate biomarkers. The more positive perspec-
tive may be based on the consideration that focusing on stable
genes may allow a quick identification of “targets” with sufficient
information whose therapeutic value can be established in sub-
sequent target validation steps. In the context of the currently
available HD datasets, all of them greatly differing at several
levels such as htt gene type, genetic background, cellular con-
text and disease stage, our bias is that genes having moderate
to high entropy values may represent candidate targets of higher
interest because manipulating their activity could more signif-
icantly impact on the homeostasis and survival of specific cell
types at a given phase (e.g., early vs. late stage) and site (e.g.,
brain/neuronal vs. peripheral pathology) of the pathogenic pro-
cess in HD. Considering additional parameters in the target gene
prioritization model such as local network entropy, proximity to
htt, brain gene expression and time requirement will refine the
view on this question.
An important aspect of entropy based systems modeling is the
context of the experiments used for gene prioritization. As illus-
trated herein, the nature and diversity of HD-related conditions
may impact on the gene content and biological profiles of signal
entropy categories. Specific experimental models may be respon-
sible for most of the entropy observed (herein, the models based
on human samples and cells), especially if the number of mod-
els is rather limited, which gains to be accounted. More largely,
using comparable rather than divergent models of disease may
change the interpretation of low-to-high entropy values in term of
clinical potential and the final selection of genes as either promis-
ing targets or markers, or both. In theory, if analyzing multiple
studies all examining for the same context (e.g., same cellular
context at the same stage of pathology vs. control), then high
entropy could indicate that a gene is unreliable, and middle-to-
low entropy might be viewed as a robust criterion for prioritizing
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FIGURE 4 | Heat-maps illustrating the biological content of
FOXO3-interaction networks as a function of gene entropy
values. Biological content is inferred using enrichment in KEGG
pathways (P < 0.001) for three (arbitrarily selected) entropy categories
corresponding to low, middle, and high entropy values. Details of
the full heat-maps can be visualized in Figures S3–5. The color
code indicates − log P -values. Gene contents are shown in Tables
S6–8.
FIGURE 5 | Context-dependent distribution of gene entropy values
in FOXO3-interaction networks. The network used in this figure is
the same as in Figure 1, except for labels of gene nodes. The
categories for gene entropy used in this figure are the same as
those in Figure 2. (A) Distribution of gene entropy values in the
context of seven murine datasets. (B) Distribution of gene entropy
values in the context of all datasets (addition of seven human
datasets).
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candidate targets. In practice, this type of situation is unlikely
to be frequently encountered. A major trend for understanding
context dependency in HD is to examine for the effects of mul-
tiple variables such as expanded-polyQ length, cellular context
and pathological stage in individual species and models, then to
select variables of interest and compare for their effects on gene
behavior across species and models. In so far, context heterogene-
ity is a constitutive element of the framework for modeling HD
datasets. High entropy is then anticipated to be relevant to several
situations in which the comparison of the molecular and biologi-
cal features that may be recapitulated by individual experimental
models (model sensitivity analysis) and the subsequent selection
of targets of interest relative to multiple contexts and variables
(target prioritization) are two complementary aspects of systems
modeling for HD.
PERSPECTIVES
System-level approaches are key to target and marker discov-
ery because these approaches are able to summarize and pri-
oritize the biological information buried in large and complex
datasets. Applying system-level approaches to the study of neu-
rodegenerative diseases such as HD is an emerging approach
that is anticipated to become widely used in the field as more
diverse genome-wide datasets. Although developing system-level
approaches requires specific skills in software computing and
mathematics, databases and knowledge discovery platforms may
become available and facilitate the access to these approaches.
There is an increasingly large repertoire of methods for the
interrogation of complex datasets and development of systems
modeling in disease research, ranging from bionetwork mapping
(Rapaport et al., 2007; Lejeune et al., 2012) to reverse engi-
neering of gene networks (Lefebvre et al., 2012) and analysis
of network rewiring response and differential entropy proper-
ties (Bandyopadhyay et al., 2010; Califano, 2011; Shou et al.,
2011; West et al., 2012). Regardless of how disease-associated
networks are generated, understanding how these networks
may differ and how they may reconfigure activity as a func-
tion of the context in which they operate is essential to gene
prioritization. In this respect, entropy-based approaches may
capture gene essentiality changes across multiple conditions
that encompass several species and models. This is particularly
attractive for studying the dynamics of chronic-stress response
networks that, similarly to FOXO-interaction networks, may
be strongly dependent on the context in which they oper-
ate. Entropy based feature selection may indeed help under-
standing how chronic-stress response networks allow specific
cell types to maintain function and resist degeneration, and
how cellular resistance may develop over time. This knowl-
edge may in turn help unraveling the clinical potential of these
networks for neurodegenerative diseases such as HD, which
might foster the identification of successful disease-modifying
strategies.
It is remarkable that longevity-promoting factors such as
FOXO proteins may have a role in development and phenotypic
plasticity (De La Torre-Ubieta et al., 2010; Christensen et al., 2011;
Tang et al., 2011; Mei et al., 2012; Salih et al., 2012). FOXO pro-
teins may thus be important throughout the entire lifetime of an
individual. This raises the possibility that FOXO proteins regu-
late developmental, post-developmental and late determinants of
the pathogenic process in HD. Today, data are relatively scarce to
study context dependency in neurodegenerative disease. However,
molecular profile data allowing context dependency to be exam-
ined in a deeper manner are becoming increasingly available, and
their analysis using systems modeling is expected to tell us more
about the clinical potential of stress response genes in HD and,
perhaps, other neurodegenerative diseases.
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The Supplementary Material for this article can be found online
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fnagi.2013.00022/abstract
Table S1 | Fourteen models of HD pathogenesis for which transcriptomic
data are available.
Table S2 | List of 6209 mouse genes including FOXO3 targets and
first-degree neighbors.
Table S3 | Entropy of FOXO3-interaction-network genes across seven HD
mouse datasets.
Table S4 | Entropy of FOXO3-interaction-network genes across seven
human HD datasets.
Table S5 | Entropy of FOXO3-interaction-network genes across 14
HD-mouse and human-HD datasets.
Table S6 | Annotation of gene-entropy categories for FOXO3 targets across
murine datasets.
Table S7 | Annotation of gene-entropy categories for FOXO3 targets across
human datasets.
Table S8 | Annotation of gene-entropy categories for FOXO3 targets across
all datasets.
Table S9 | Annotation of gene-entropy categories for the entire
FOXO3-interaction network across murine datasets.
Table S10 | Annotation of gene-entropy categories for the entire
FOXO3-interaction network across human datasets.
Table S11 | Annotation of gene-entropy categories for entire
FOXO3-interaction network across all datasets.
Figure S1 | Heat-map representing the biological content for 350 mouse
FOXO3 targets and their 5859 first neighbors (STRING confidence score
greater than 0.4). Biological annotations are inferred from KEGG pathways.
The cut-off for enrichment in KEGG pathways is P < 0.05 for the FOXO3
targets and P < 0.0001 for their first-degree neighbors.
Figure S2 | Statistical comparison of gene entropy values following
permutation analysis in FOXO-interaction networks. Increasing numbers
of FOXO3 targets (from 10 to 260 genes, in increment of 10 genes)
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and their first neighbors were randomly replaced by genes that
belong to the STRING network and that are instructed by at least
6 HD-related conditions in either the mouse or human datasets,
and this was performed 1000’s of times. The Kolmogorov-Smirnov
test was then used to compare the distributions of entropy values.
Differences between distributions before and after n permutations
(Y axis) are shown for P < 0.05 (red curves) and P < 0.01 (blue
curves). One hundred percentage of the shuffled differences are
statistically significant for replacement of less than 80–100 (mouse
datasets) to 60–70 (human datasets) genes, suggesting that
FOXO-interaction networks have specific entropy features. The
number of permuted genes required to significantly alter the initial
distributions of entropy values was greater for the mouse datasets
compared to the human datasets, which reflects stronger
heterogeneity in human datasets.
Figure S3 | Heat-map representing the biological content for low to high
entropy genes in the FOXO3-interaction network and across seven mouse
models (striatum) of HD. Biological content is inferred from enrichment in
KEGG pathways (P < 0.001).
Figure S4 | Heat-map representing the biological content for low to high
entropy genes in the FOXO3-interaction network and across seven human
HD (post-mortem caudate nucleus and cortex, blood samples from
pre-and post-symptomatic HD subjects, iPS cells) datasets. Biological
content is inferred from enrichment in KEGG pathways (P < 0.001).
Figure S5 | Heat-map representing the biological content for low to high
entropy genes in the FOXO3-interaction network and across seven mouse
models of HD (striatum) and seven human HD (post-mortem caudate
nucleus and cortex, blood samples from pre-and post-symptomatic HD
subjects, iPS cells) datasets. Biological content is inferred from
enrichment in KEGG pathways (P < 0.001).
Figure S6 | Graph showing the distribution of entropy values in a KEGG
pathway (here “Long-term potentiation”) that is specifically enriched in
genes with high entropy values (see Figure 4).
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